Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Income from Continuing Operations (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Income from Continuing Operations for 15 consecutive years, with 5713000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 46.37% to 5713000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 15730000.0 through Dec 2025, down 7.73% year-over-year, with the annual reading at 15730000.0 for FY2025, 7.73% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 5713000.0 at Plus Therapeutics, down from 4423000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 1482000.0 in Q2 2023, with the low at 5713000.0 in Q4 2025.
  • Average Income from Continuing Operations over 5 years is 3849315.79, with a median of 3810000.0 recorded in 2023.
  • The sharpest move saw Income from Continuing Operations skyrocketed 72.04% in 2023, then tumbled 146.76% in 2024.
  • Over 5 years, Income from Continuing Operations stood at 3726000.0 in 2021, then plummeted by 50.56% to 5610000.0 in 2022, then soared by 32.09% to 3810000.0 in 2023, then decreased by 2.44% to 3903000.0 in 2024, then crashed by 46.37% to 5713000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 5713000.0, 4423000.0, and 1511000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.